rs2736990 — SNCA

SNCA rs2736990 — The Intron 4 Variant That Tags Independent Alpha-Synuclein Risk

The SNCA gene¹¹ SNCA gene
Alpha-synuclein (SNCA) encodes the protein that aggregates into Lewy bodies — the pathological hallmark of Parkinson's disease and related synucleinopathies harbors multiple independent risk variants, each tagging different biological mechanisms at the same locus. rs2736990 sits within intron 4 of SNCA — a region known for a complex CT-rich haplotype structure that influences alpha-synuclein expression and splicing²² complex CT-rich haplotype structure that influences alpha-synuclein expression and splicing — and was the first intronic SNCA variant to reach genome-wide significance in a large European GWAS.

What distinguishes rs2736990 from the other SNCA risk variants profiled in this database (rs356219 and rs356182) is its position in a different linkage disequilibrium (LD) block. The three variants are not correlated with each other by descent, meaning they carry independent risk information. Carriers of the G allele at rs2736990 face meaningfully elevated Parkinson's disease risk regardless of their genotype at the other SNCA loci, and the G allele associates specifically with earlier disease onset and cognitive vulnerability — the same clinical phenotype seen with rs356219, suggesting a shared downstream mechanism related to alpha-synuclein protein levels.

The Mechanism

rs2736990 is classified as an intronic variant³³ intronic variant
A variant located within a non-coding region of a gene (intron); intronic variants can influence gene expression, splicing efficiency, or RNA stability without changing the protein sequence in intron 4 of SNCA. The precise molecular mechanism by which this variant alters disease risk is not fully established, but the leading hypothesis is that it influences SNCA pre-mRNA splicing or expression levels — consistent with the known biology of the intron 4 region. The intron 4 of SNCA is a hotspot for structural variation and CT-repeat polymorphisms (REP1), and rs2736990 is embedded in this functionally active region.

The net effect, supported by population data, is that G-allele carriers have higher circulating alpha-synuclein levels compared to AA carriers — paralleling the mechanism of rs356219. Elevated alpha-synuclein creates a permissive environment for misfolding, oligomer formation, and progressive dopaminergic neuron death in the substantia nigra. Because the variant is intronic, it does not change the alpha-synuclein protein itself but modulates how much of it is produced or how efficiently the mRNA is processed.

The Evidence

The discovery of rs2736990 as a Parkinson's disease risk variant came from a landmark 2009 European genome-wide association study⁴⁴ a landmark 2009 European genome-wide association study
Simón-Sánchez et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 2009 that enrolled 1,713 cases and 3,978 controls, with replication in an independent cohort of 3,361 cases and 4,573 controls. The SNCA signal at rs2736990 was one of the two strongest associations identified, with OR 1.23 and p=2.24×10⁻¹⁶ — a highly robust association by GWAS standards.

A Chinese Han case-control study⁵⁵ A Chinese Han case-control study
Association of polymorphism in rs2736990 of the α-synuclein gene with Parkinson's disease in a Chinese population. Neurology India, 2013 (515 PD patients, 450 controls) confirmed the C allele as a PD risk factor (OR 1.26, 95% CI 1.04–1.51; p=0.017) and identified a stronger effect in early-onset patients diagnosed at or before age 50 (OR 1.60, 95% CI 1.13–2.26; p=0.007). This early-onset enrichment is clinically significant — it suggests that among younger PD patients, rs2736990 is playing a more prominent etiological role.

A 2017 meta-analysis⁶⁶ 2017 meta-analysis
Association between SNCA rs2736990 polymorphism and Parkinson's disease: a meta-analysis. Neuroscience Letters, 2017 pooling six studies (2,525 PD cases, 2,165 controls) formally established the risk direction: the C allele (G on plus strand) confers increased risk, with an allele model OR of 1.30. Under the recessive model (CC vs TT+TC), the OR for the homozygous risk genotype was 1.52.

The 2017 Brazilian cohort⁷⁷ 2017 Brazilian cohort
Campelo et al. Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample. Frontiers in Aging Neuroscience, 2017 (104 PD patients, 98 controls) provided crucial data linking rs2736990 directly to cognitive outcomes. The CC homozygous genotype was associated with OR 2.65 (95% CI 1.13–6.20) for PD overall, and the C allele was significantly more frequent among PD patients with cognitive impairment (70%) versus controls (52%), yielding OR 2.21 (95% CI 1.26–3.85; p=0.005). The C allele also associated with early-onset PD (OR 1.88, 95% CI 1.07–3.29; p=0.028). Notably, this study found that rs2736990 and rs356219 co-occur in a risk haplotype (OR 2.51 for the combined haplotype), confirming their independent but additive contributions.

The largest systematic assessment comes from a 2018 comprehensive meta-analysis⁸⁸ 2018 comprehensive meta-analysis
A Comprehensive Analysis of the Association Between SNCA Polymorphisms and the Risk of Parkinson's Disease. Frontiers in Molecular Neuroscience, 2018 covering 24,075 cases and 22,877 controls across 36 studies. Among 16 SNCA variants analyzed, rs2736990 was classified as one of eight "most recommended" variants (p<1×10⁻⁵) for genetic risk assessment, with OR 1.22 in the allele model (95% CI 1.13–1.31) and OR 1.30 in both dominant and recessive models. The G allele frequency in unaffected controls was 0.56 globally and 0.62 in East Asian controls, confirming the variant is common — not a rare pathogenic mutation, but a frequent risk-modifying variant.

Practical Actions

The actionable profile for rs2736990 is closely related to that of rs356219, since both variants elevate alpha-synuclein levels and both associate with earlier disease onset and cognitive vulnerability. The key targets are mitochondrial dysfunction, oxidative stress that promotes alpha-synuclein misfolding, and impaired autophagy — the cellular cleanup system that normally clears misfolded protein aggregates.

Ubiquinol CoQ10 addresses the mitochondrial complex I dysfunction⁹⁹ Ubiquinol CoQ10 addresses the mitochondrial complex I dysfunction that alpha-synuclein overload drives, while simultaneously reducing the oxidative environment that promotes further misfolding. Regular caffeinated coffee intake shows consistent neuroprotective associations in PD epidemiology¹⁰¹⁰ Regular caffeinated coffee intake shows consistent neuroprotective associations in PD epidemiology, with caffeine shown to reduce alpha-synuclein oligomer toxicity and restore autophagy-mediated clearance of misfolded protein.

For G-allele carriers who are younger or have a family history of PD, establishing a neurological baseline and monitoring for early prodromal signs (hyposmia, REM sleep behavior disorder, constipation, subtle motor asymmetry) is particularly valuable given this variant's association with earlier onset.

Interactions

rs2736990 is independent of both rs356219 and rs356182 at the SNCA locus — each resides in a different LD block. Carriers of risk alleles at multiple SNCA loci face cumulative risk: the 2017 Brazilian study explicitly showed that a haplotype combining rs356219 G and rs2736990 C alleles carries OR 2.51 for PD — higher than either variant alone. This additive relationship suggests that individuals who carry G alleles at both rs2736990 and rs356219 represent a particularly high-priority group for early monitoring and neuroprotective lifestyle strategies.

The early-onset association of rs2736990 has been replicated independently across Mexican, Chinese, and Brazilian populations, suggesting a consistent biological mechanism tied to the intron 4 region's regulatory function.